Idelalisib is a phosphoinositide 3-kinase (PI3K) inhibitor used for the treatment of chronic lymphocytic leukemia and follicular lymphoma. Clinical responses to idelalisib vary widely, and have not been explained by clinical features or somatic variation. This study investigated potential genetic and epigenetic contributors to variability in drug response. In the project lead by Drs. Kristen Pettit and Eileen Dolan, I have performed a genome-wide association study, eQTL enrichment analysis, and correlation of the drug response with RNA expression data in HapMap YRI cell lines to explore the pharmacogenomic variants associated with cellular sensitivity to Idelalisib.
The abstract submitted by Dr. Pettit to the annual ASCPT has been selected for showcase of top trainee abstracts.
Publication in preparation.